Helus: Helus PharmaTM ('Helus') (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company focused on developing novel serotonergic agonists, has announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.

According to BERNAMA News Agency, Mr. Cola's appointment is strategically timed as Helus is poised to advance its pipeline of mental health therapies towards significant clinical and corporate milestones. This includes the anticipated release of Phase 2 data for HLP004 within this quarter and Phase 3 topline data for HLP003 expected in the fourth quarter of 2026. Concurrently, Helus is expanding its intellectual property portfolio, having filed over 350 patent applications globally and secured more than 100 patents.

Helus is focused on developing differentiated programs targeting serious mental health disorders. As the company transitions from early-stage clinical development to later-stage execution, it emphasizes global regulatory engagement and long-term commercial planning. This strategic shift highlights the necessity for experienced leadership in drug development, capital formation, and global expansion.